NASDAQ$COCP
Cocrystal Pharma Inc · Q1 2026 earnings
Q1 2026 earnings · · Investor relations
Briefing
Cocrystal Pharma reported a net loss of $2.3 million for the first quarter of 2026 while advancing its antiviral pipeline.
Cocrystal Pharma Inc. recorded grant income of $225,000 and a net loss of $2.3 million for the quarter ended March 31, 2026. Research and development expenses were $1.4 million as the company progressed clinical studies for norovirus and influenza candidates. The company ended the quarter with $4.7 million in cash and emphasized the need for additional capital to fund ongoing operations.
- Grant income of $225,000 recognized from NIH/NIAID SBIR award for influenza program.
- Net loss of $2.3 million with R&D expenses of $1.4 million supporting antiviral development.
- Cash position declined to $4.7 million; substantial doubt about going concern raised.
- Phase 1b norovirus challenge study initiated with CDI-988; Fast Track designation received.
Headline financials
Revenue & EPS history
Cocrystal Pharma · Revenue · Quarterly
$225K
Forward guidance
Company expects to continue incurring substantial operating losses and requires additional capital to fund operations beyond the next 12 months.
Tailwinds
- Fast Track designation received for CDI-988
- Phase 1b norovirus challenge study initiated
Headwinds
- Substantial doubt about ability to continue as going concern
- Current cash insufficient for 12 months of operations
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2026
-0.9%
Avg return
Earnings day
+0.4%
Avg return
5 days after
+1.4%
Avg return
30 days after
33%
19 / 58 earnings
Positive
+25.0%
Q3 2024
Best reaction
-33.3%
Q1 2013
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -5.6% | -11.9% | — | |
| Q4 2026 | -2.9% | +51.0% | +43.0% | |
| Q3 2025 | +0.0% | -3.9% | +1.9% | |
| Q2 2025 | -1.2% | -8.9% | -6.0% | |
| Q1 2025 | -7.4% | +4.1% | +5.5% | |
| Q4 2024 | +4.1% | +6.5% | +23.6% | |
| Q3 2024 | +25.0% | +17.6% | +8.5% | |
| Q2 2024 | -10.0% | +10.5% | -12.1% | |
| Q1 2024 | +8.1% | +12.7% | +61.8% | |
| Q4 2023 | +0.0% | -1.3% | +4.0% | |
| Q3 2023 | -1.1% | -11.1% | -5.3% | |
| Q2 2023 | +2.1% | -5.9% | -31.1% | |
| Q1 2023 | -3.8% | -13.2% | -3.8% | |
| Q4 2022 | +4.4% | +8.3% | +37.8% | |
| Q3 2022 | +0.0% | -3.3% | -19.5% | |
| Q2 2022 | +0.0% | -8.7% | -23.9% | |
| Q1 2022 | -5.0% | +0.0% | +2.5% | |
| Q4 2021 | +1.7% | -1.7% | -12.1% | |
| Q3 2021 | -2.2% | -9.9% | -22.0% | |
| Q2 2021 | +2.9% | -1.0% | +2.9% | |
| Q1 2021 | +2.7% | +1.8% | +15.0% | |
| Q4 2020 | -5.0% | -2.5% | -24.5% | |
| Q3 2020 | -2.3% | +2.3% | +64.4% | |
| Q2 2020 | -7.3% | -10.5% | -58.6% | |
| Q1 2020 | -2.8% | -1.4% | +30.6% | |
| Q4 2019 | +5.9% | +2.9% | +33.8% | |
| Q3 2019 | -21.0% | -30.6% | -25.8% | |
| Q2 2019 | -10.8% | -14.9% | -34.0% | |
| Q1 2019 | +0.7% | -1.1% | -5.5% | |
| Q4 2018 | +0.7% | -1.1% | -5.5% | |
| Q3 2018 | +6.8% | +42.2% | +91.7% | |
| Q2 2018 | -5.5% | -4.3% | -19.4% | |
| Q1 2018 | +5.0% | -14.5% | -64.4% | |
| Q4 2017 | -2.1% | +10.9% | -30.0% | |
| Q4 2016 | +0.0% | +0.0% | -11.5% | |
| Q3 2017 | +0.0% | +0.0% | -11.5% | |
| Q2 2017 | +0.0% | +0.0% | +52.6% | |
| Q1 2017 | +0.0% | +15.4% | +3.8% | |
| Q3 2016 | +0.0% | -8.2% | -12.2% | |
| Q2 2016 | +4.4% | +0.0% | +11.1% | |
| Q4 2015 | -3.1% | — | — | |
| Q1 2016 | +7.0% | — | — | |
| Q3 2015 | +0.0% | — | — | |
| Q2 2015 | +0.0% | — | — | |
| Q1 2015 | +16.7% | — | — | |
| Q4 2014 | +16.7% | — | — | |
| Q3 2014 | +0.0% | — | — | |
| Q2 2014 | +12.1% | — | — | |
| Q1 2014 | +12.1% | — | — | |
| Q4 2013 | -3.3% | — | — | |
| Q3 2013 | -21.1% | — | — | |
| Q2 2013 | +0.0% | — | — | |
| Q4 2012 | -33.3% | — | — | |
| Q1 2013 | -33.3% | — | — | |
| Q3 2012 | +0.0% | — | — | |
| Q2 2012 | +0.0% | — | — | |
| Q1 2012 | +0.0% | — | — | |
| Q2 2011 | +0.0% | — | — | |
| Q4 2011 | — | — | — | |
| Q3 2010 | — | — | — | |
| Q3 2011 | — | — | — | |
| Q4 2010 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro